Handelsavisen
prelaunch
Companies Healthcare NVAX.O
NV
NVAX.O NASDAQ Biotechnology

Nvax.O

$7,47
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
1,2B USD
P/E
EV / Rev
1,6x
Div yield
Op margin
-17,9 %
ROE
68,8 %
Net margin
-14,7 %
Debt / equity
Beta
52w range
Volume
3
Day range
Prev close
$7,44
Open
$7,43
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Novavax Inc operates as a biotechnology company within the Health Care sector, generating revenue primarily through vaccine development and commercialization activities.

Business. Novavax Inc operates as a biotechnology company within the Health Care sector, generating revenue primarily through vaccine development and commercialization activities.

Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
HOLD9 analysts
5 buy1 hold3 sell
Avg 12m price target14,11

Analyst recommendations

9 analysts · consensus Hold
Buy5
Hold1
Sell3
12-month price target
14,11
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Hold
9 analysts · indicative
Ownership
UBS Financial Services, Inc.
largest disclosed fund holder
Profitability
68,8 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning NVAX.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to NVAX.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Novavax Inc operates as a biotechnology company within the Health Care sector, generating revenue primarily through vaccine development and commercialization activities.

    Classification85 %
    SectorHealth Care
    Industry groupBiotechnology
    AI synthesis
    GENERATED

    (a) Capital structure and liquidity present a complex profile. The company reports total assets of $1.18 billion against total liabilities of $1.30 billion, resulting in negative total equity of -$128 million. Cash and equivalents stand at $241 million, providing a buffer against immediate obligations. However, operating cash flow is negative at -$245 million, indicating that core operations are consuming cash rather than generating it. The debt-to-equity ratio is reported as -0.0, reflecting the negative equity base. The current ratio is not explicitly provided, but the negative equity position suggests a fragile balance sheet structure that relies heavily on cash reserves and potential external financing.

    (b) Profitability metrics show mixed signals. The company generated net income of $440 million on revenue of $1.12 billion, yielding a return on equity of 68.75%. This high ROE is mechanically driven by the small, negative equity base rather than operational efficiency. Return on assets is negative at -7.47%, indicating that the asset base is not generating positive returns relative to its size. Without cohort median data for direct comparison, the negative ROA and negative operating cash flow suggest that the company is in a growth or turnaround phase where capital investment exceeds immediate returns. The EV/EBITDA ratio is negative at -9.13, further highlighting the lack of positive EBITDA generation.

    Key takeaways
    • Negative equity of -$128 million and negative operating cash flow of -$245 million indicate a fragile financial position reliant on cash reserves.
    • High return on equity of 68.75% is driven by negative equity rather than operational efficiency, while return on assets is negative at -7.47%.
    • Analyst sentiment is moderately positive with a mean price target of $14.11 and a mean recommendation of 2.67, suggesting upside potential from the current market price of $7.48.
    • Low liquidity and dilution risks are flagged, but the negative equity and cash burn present inherent financial risks that require monitoring.
    • Absence of historical data and segment/geographic breakdowns limits the ability to assess growth trends and revenue concentration risks.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-05-06
    Q1 2026 · Quarter highlights
    Open report →

    Revenue $139.5M, −79,1% YoY; Operating income −103,0% YoY.

    Revenue$139.5M−79,1 % YoY
    Operating income-$15.4M−103,0 % YoY
    Net income-$9.5M−101,8 % YoY
    Free cash flow-$7.7M−101,5 % YoY
    EPS
    Operating cash flow-$32.4M+82,5 % YoY
    Financials
    Income statement
    Revenue$139.5M
    Gross profit$108.8M
    Operating income-$15.4M
    Net income-$9.5M
    Margins
    Gross margin78.0%
    Operating margin-11.1%
    Net margin-6.8%
    FCF margin-5.5%
    Balance sheet
    Total assets$1.04B
    Total liabilities$1.19B
    Total equity-$144.8M
    Cash & equivalents$228.4M
    Long-term debt$295.1M
    Cash flow
    Operating cash flow-$32.4M
    CapEx-$1.3M
    Free cash flow-$7.7M
    SBC
    P&L flow · revenue → net income
    Revenue $139.5MOperating costs $154.9MNet income $9.5M
    Highlights
    • Revenue $139.5M, −79,1% YoY
    • Operating income −103,0% YoY
    • Net income −101,8% YoY
    • Free cash flow −101,5% YoY
    • Net margin -6.8%

    Valuation TTM

    Market price
    $7,47
    Market cap
    $1.22B
    Enterprise value
    $975.4M
    P/E
    Non-GAAP P/E
    EV / Revenue
    1.6x
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    -$127.8M
    Net cash
    $240.6M
    Current ratio
    Debt / equity
    ROA
    -7.5%
    ROE
    68.8%
    Cash conversion
    279.0%
    CapEx / revenue
    -0.9%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    Business relationships13 disclosed relationships · 2 types · extracted from filings & disclosures
    Partners3
    Pfizer IncPFE.TOPartner100%Source ↗
    SANOFISNY.OPartner100%Source ↗
    Subsidiaries10
    EX21:1e72769c51d1EX21:1e72769c51d1Subsidiarie97%
    EX21:21dafef8ff77EX21:21dafef8ff77Subsidiarie97%
    EX21:4fb1ddba092fEX21:4fb1ddba092fSubsidiarie97%
    EX21:51034a8cfcf5EX21:51034a8cfcf5Subsidiarie97%
    EX21:805500be830eEX21:805500be830eSubsidiarie97%
    EX21:a959792ed6adEX21:a959792ed6adSubsidiarie97%
    EX21:c72eebe79e9bEX21:c72eebe79e9bSubsidiarie97%Source ↗
    EX21:d053d2350f55EX21:d053d2350f55Subsidiarie97%
    EX21:e4880f8a61a1EX21:e4880f8a61a1Subsidiarie97%
    EX21:f661d01f524cEX21:f661d01f524cSubsidiarie97%

    Supply chain

    Vendors → NVAX ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSNVAXNVAXNvax.O13 entitiesPfizer IncPharmaceuticalsCASANOFIPharmaceuticalsUSTakeda Pharmaceutical PharmaceuticalsJP
    3 mentions in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-06-24

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,46
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    9
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-07-31 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-0,46
    Revenueno estimateno estimate387,3M USD
    Operating incomeno estimateno estimate-93,2M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Corporate eventM&A horizon
    M&A probabilityconf 5 %
    Probability
    5 %
    Base rate
    3 %
    Band
    180-day horizon · target 2027-01-23 · 1,8× base rate
    No acquirer candidates identified by the signal model.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution9 analysts
    Strong buy2
    Buy3
    Hold1
    Sell2
    Strong sell1
    12-month price target$14,11 · Median $16,00
    Low $7,00High $25,00
    Operating income · consensus-93,2M USD
    EPS surprise
    +667,0 %
    reported vs consensus · beat
    Revenue surprise
    +190,1 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$7,00
    Mean$14,11
    Median$16,00
    High$25,00
    Spot$7,47
    +88.9 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-17,9 %Above median
    Net Margin-14,7 %Above median
    ROE68,8 %Best in class
    Capex / Rev-0,9 %Below median
    D/E-0,00Above median
    Cash Conv2,79Best in class

    Corporate actions / M&A

    M&A probabilityconf —
    Probability
    5 %
    Base rate
    3 %
    Band
    Moderate
    180-day horizon · target 2027-01-23 · 1,8× base rate
    No acquirer candidates identified by the signal model.
    Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 1 704 343 sh19 exercises · 28 grants14 insiders
    • King Rachel K.Director · Restricted Stock Units → Common StockDisposed 18 880exercise · 2026-06-20
    • DOUGLAS RICHARDDirector · Restricted Stock Units → Common StockDisposed 18 880exercise · 2026-06-20
    • Alton Gregg HDirector · Restricted Stock Units → Common StockDisposed 18 880exercise · 2026-06-20
    • MOTT DAVID MDirector · Restricted Stock Units → Common StockDisposed 18 880exercise · 2026-06-20
    • MCGLYNN MARGARET GDirector · Restricted Stock Units → Common StockDisposed 18 880exercise · 2026-06-20
    • Rodgers Richard JDirector · Restricted Stock Units → Common StockDisposed 18 880exercise · 2026-06-20
    • MOTT DAVID MDirector · Stock Option (Right to Buy) → Common StockAcquired 21 270 @ $9,13grant · 2026-06-18
    • Alton Gregg HDirector · Restricted Stock Units → Common StockAcquired 14 180grant · 2026-06-18
    • MOTT DAVID MDirector · Restricted Stock Units → Common StockAcquired 14 180grant · 2026-06-18
    • Alton Gregg HDirector · Stock Option (Right to Buy) → Common StockAcquired 21 270 @ $9,13grant · 2026-06-18
    • Shiver John W.Director · Stock Option (Right to Buy) → Common StockAcquired 21 270 @ $9,13grant · 2026-06-18
    • Shiver John W.Director · Restricted Stock Units → Common StockAcquired 14 180grant · 2026-06-18
    • MCGLYNN MARGARET GDirector · Stock Option (Right to Buy) → Common StockAcquired 21 270 @ $9,13grant · 2026-06-18
    • DOUGLAS RICHARDDirector · Restricted Stock Units → Common StockAcquired 14 180grant · 2026-06-18
    • DOUGLAS RICHARDDirector · Stock Option (Right to Buy) → Common StockAcquired 21 270 @ $9,13grant · 2026-06-18
    • Rodgers Richard JDirector · Stock Option (Right to Buy) → Common StockAcquired 21 270 @ $9,13grant · 2026-06-18
    • Rodgers Richard JDirector · Restricted Stock Units → Common StockAcquired 14 180grant · 2026-06-18
    • King Rachel K.Director · Restricted Stock Units → Common StockAcquired 14 180grant · 2026-06-18
    • King Rachel K.Director · Stock Option (Right to Buy) → Common StockAcquired 21 270 @ $9,13grant · 2026-06-18
    • MCGLYNN MARGARET GDirector · Restricted Stock Units → Common StockAcquired 14 180grant · 2026-06-18
    • Newton Charles W.Director · Restricted Stock Units → Common StockAcquired 14 180grant · 2026-06-18
    • Newton Charles W.Director · Stock Option (Right to Buy) → Common StockAcquired 21 270 @ $9,13grant · 2026-06-18
    • Newton Charles W.Director · Restricted Stock Units → Common StockDisposed 9 520exercise · 2026-04-25
    • Walker Robert EdwardEVP, R&D · Stock Option (Right to Buy) → Common StockAcquired 99 500 @ $8,46grant · 2026-04-14
    • Walker Robert EdwardEVP, R&D · Restricted Stock Units → Common StockAcquired 66 000grant · 2026-04-14

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Reference data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Ev To Revenue
      enterprise_value / revenue
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • NOVAVAX, INC. Market data — financials · 2026-07-31
    • reconciler_enqueue (reconciler) on NVAX.O · 2026-07-31
    • Novavax Inc Market data — analyst estimates · 2026-07-31
    • Novavax Inc Market data — ESG · 2026-07-31
    • NVAX.O HA canonical relationships · 2026-07-31

    Ownership & reference

    Top holders

    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,01 %$36M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$150M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$73M
    • First Trust Advisors L.P.Investment Managers · as of 2026-03-310,00 %$3M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$32M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$11M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$12M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$11M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$104M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$6M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$3M
    • MASSACHUSETTS FINANCIAL SERVICES CO /MA/Institutional Investor · as of 2026-03-310,00 %$1M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$1M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$2M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$5M
    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$0M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$1M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$1M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$2M
    • Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
    • Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,00 %$0M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$0M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Leadership

    • John C. JacobsPresident, Chief Executive Officer, Director

    Insider activity

    Mixed / flat0 buys · 0 sellsnet $013 insiders · last 365d
    • MOTT DAVID MDirector · Common StockOther 18 880 · 2026-06-20
    • Alton Gregg HDirector · Common StockOther 18 880 · 2026-06-20
    • Rodgers Richard JDirector · Common StockOther 18 880 · 2026-06-20
    • King Rachel K.Director · Common StockOther 18 880 · 2026-06-20
    • DOUGLAS RICHARDDirector · Common StockOther 18 880 · 2026-06-20
    • MCGLYNN MARGARET GDirector · Common StockOther 18 880 · 2026-06-20
    • Newton Charles W.Director · Common StockOther 9 520 · 2026-04-25
    • Shiver John W.Director · Common StockOther 7 947 · 2026-03-10
    • Kelly James PatrickEVP, CFO and Treasurer · Common StockOther 12 223 · 2026-03-07
    • Kelly James PatrickEVP, CFO and Treasurer · Common StockOther 5 904 @ $9,98$59K · 2026-03-07
    • Kelly James PatrickEVP, CFO and Treasurer · Common StockOther 43 167 · 2026-03-03
    • Kelly James PatrickEVP, CFO and Treasurer · Common StockOther 20 850 @ $9,49$198K · 2026-03-03
    • Jacobs John CDirector, President and CEO · Common StockOther 150 167 · 2026-03-03
    • Jacobs John CDirector, President and CEO · Common StockOther 69 288 @ $9,49$658K · 2026-03-03
    • O'Hara ElaineEVP, Chief Strategy Officer · Common StockOther 56 334 · 2026-03-03
    • O'Hara ElaineEVP, Chief Strategy Officer · Common StockOther 22 429 @ $9,49$213K · 2026-03-03
    • Casey Mark JEVP, Chief Legal Officer · Common StockOther 37 500 · 2026-03-03
    • Casey Mark JEVP, Chief Legal Officer · Common StockOther 11 378 @ $9,49$108K · 2026-03-03
    • Draghia-Akli RuxandraEVP, Research & Development · Common StockOther 26 667 · 2026-03-03
    • Draghia-Akli RuxandraEVP, Research & Development · Common StockOther 11 313 @ $9,49$107K · 2026-03-03
    • Jacobs John CDirector, President and CEO · Common StockOther 83 333 · 2026-03-01
    • Jacobs John CDirector, President and CEO · Common StockOther 38 450 @ $10,14$390K · 2026-03-01
    • Kelly James PatrickEVP, CFO and Treasurer · Common StockOther 58 666 · 2026-03-01
    • Kelly James PatrickEVP, CFO and Treasurer · Common StockOther 28 366 @ $10,14$288K · 2026-03-01
    • O'Hara ElaineEVP, Chief Strategy Officer · Common StockOther 19 600 · 2026-03-01

    Short positioning

    43.8Mshares short-4.3% vs prior
    11.43days to cover
    52.9%short of daily vol
    195.3Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    NVAX.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00M&A prob5 %Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.
    Relationship graph
    NVAXPFE.TOSNY.O4502.TEX21:1e7EX21:21dEX21:4fbEX21:510EX21:805EX21:a95EX21:c72Biotechnology
    This companySectorPartnersSubsidiaries

    Evidence & claims

    From filings & derived data
    • Shares outstanding (annual): 162.58MUnknown
    • Total liabilities (annual): USD 1.3BUnknown
    • EPS (diluted) (annual): USD-PER-SHARES 3Unknown
    • Operating income (annual): USD 452.8MUnknown
    • Net income (annual): USD 440.3MUnknown
    • Cash & equivalents (annual): USD 240.63MUnknown
    • Current liabilities (annual): USD 459.95MUnknown
    • Shareholders' equity (annual): USD -127.75MUnknown
    • Long-term debt (annual): USD 244.21MUnknown
    • Operating cash flow (annual): USD -244.63MUnknown
    • Cost of revenue (annual): USD 73.04MUnknown
    • Revenue (annual): USD 1.12BUnknown
    • Total assets (annual): USD 1.18BUnknown
    • Pre-tax income (annual): USD 442.17MUnknown
    • EPS (basic) (annual): USD-PER-SHARES 3Unknown
    • R&D expense (annual): USD 342.32MUnknown
    • Current assets (annual): USD 978.28MUnknown
    • Cash & equivalents (annual): USD 530.23MUnknown
    • Current liabilities (annual): USD 1.15BUnknown
    • Shares outstanding (annual): 160.42MUnknown
    • Operating income (annual): USD -248.93MUnknown
    • Cost of revenue (annual): USD 202.74MUnknown
    • Revenue (annual): USD 682.16MUnknown
    • Net income (annual): USD -187.5MUnknown
    Showing 24 of 33 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
    2026-06-28 03:14 UTCHOLDERInstitutional holding changed
    2026-06-28 03:14 UTCHOLDER1 institutional position change flagged
    2026-06-20 00:00 UTCINSIDER28 insider transactions — 2026-06 22 derivative
    2026-06-20 00:00 UTCINSIDER28 insider transactions — 2026-06 22 derivative
    2026-06-20INSIDERMOTT DAVID M transacted 18.9k sh — Director
    2026-06-20INSIDERAlton Gregg H transacted 18.9k sh — Director
    2026-06-20INSIDERRodgers Richard J transacted 18.9k sh — Director
    2026-06-20INSIDERKing Rachel K. transacted 18.9k sh — Director
    2026-06-20INSIDERDOUGLAS RICHARD transacted 18.9k sh — Director
    2026-06-20INSIDERMCGLYNN MARGARET G transacted 18.9k sh — Director
    2026-06-20INSIDERMOTT DAVID M disposed of 18.9k sh Restricted Stock Units — Director
    2026-06-20INSIDERRodgers Richard J disposed of 18.9k sh Restricted Stock Units — Director
    2026-06-20INSIDERMCGLYNN MARGARET G disposed of 18.9k sh Restricted Stock Units — Director
    2026-06-20INSIDERAlton Gregg H disposed of 18.9k sh Restricted Stock Units — Director
    2026-06-20INSIDERDOUGLAS RICHARD disposed of 18.9k sh Restricted Stock Units — Director
    2026-06-20INSIDERKing Rachel K. disposed of 18.9k sh Restricted Stock Units — Director
    2026-06-18INSIDERDOUGLAS RICHARD acquired 14.2k sh Restricted Stock Units — Director
    2026-06-18INSIDERMCGLYNN MARGARET G acquired 14.2k sh Restricted Stock Units — Director
    2026-06-18INSIDERMOTT DAVID M acquired 21.3k sh Stock Option (Right to Buy) — Director
    2026-06-18INSIDERMOTT DAVID M acquired 14.2k sh Restricted Stock Units — Director
    2026-06-18INSIDERMCGLYNN MARGARET G acquired 21.3k sh Stock Option (Right to Buy) — Director
    2026-06-18INSIDERDOUGLAS RICHARD acquired 21.3k sh Stock Option (Right to Buy) — Director
    2026-06-18INSIDERKing Rachel K. acquired 21.3k sh Stock Option (Right to Buy) — Director
    2026-06-18INSIDERShiver John W. acquired 21.3k sh Stock Option (Right to Buy) — Director
    2026-06-18INSIDERShiver John W. acquired 14.2k sh Restricted Stock Units — Director
    2026-06-18INSIDERRodgers Richard J acquired 14.2k sh Restricted Stock Units — Director
    2026-06-18INSIDERAlton Gregg H acquired 14.2k sh Restricted Stock Units — Director
    2026-06-18INSIDERAlton Gregg H acquired 21.3k sh Stock Option (Right to Buy) — Director
    2026-06-18INSIDERRodgers Richard J acquired 21.3k sh Stock Option (Right to Buy) — Director
    2026-06-18INSIDERKing Rachel K. acquired 14.2k sh Restricted Stock Units — Director
    2026-06-18INSIDERNewton Charles W. acquired 14.2k sh Restricted Stock Units — Director
    2026-06-18INSIDERNewton Charles W. acquired 21.3k sh Stock Option (Right to Buy) — Director
    2026-05-06 07:51 UTCEARNINGSQuarterly results — Q1 2026 Revenue USD 139.5M · Net USD -9.5M
    2026-05-06FILING8-K filing →
    2026-05-06FILING10-Q filing →
    2026-04-27FILINGDEF 14A filing →
    2026-04-25 00:00 UTCINSIDER4 insider transactions — 2026-04 3 derivative
    2026-04-25 00:00 UTCINSIDER4 insider transactions — 2026-04 3 derivative
    Showing the 40 most recent of 77 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Reference data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage